<DOC>
	<DOCNO>NCT01885247</DOCNO>
	<brief_summary>The management patient Obstructive Chronic BronchoPneumopathy ( OCBP ) base progression therapeutic option sensitization physical activity . For patient select OCBP stage 2 , treatment option include Long Acting Beta-Agonist Bronchodilator ( LABA ) Long Acting Muscarinic Antagonist Anticholinergic ( LAMA ) ( LAMA+LABA ) . The purpose study observe common clinical practice benefit physical activity quality life , dyspnoea walk distance patient treatment ( LABA and/or LAMA ) determine whether 3 medical strategy ( LABA/LAMA/LABA+LAMA ) benefit physical activity .</brief_summary>
	<brief_title>4-10 Week Observational Study Comparing 3 Management Strategies Obstructive Chronic BronchoPneumopathy ( OCBP ) Common Clinical Practice</brief_title>
	<detailed_description />
	<criteria>Patients Obstructive Chronic BronchoPneumopathy stage â‰¥ 2 . Patients treatment LABA LAMA LABA+LAMA since least 1 month . VEMS/CVF &lt; 70 % VEMS &lt; 80 % Patients without regular physical activity without physical activity program since 1 year . Patients treatment LABA + inhale Corticoids . Contraindication physical activity . Patients previous history respiratory exacerbation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>